One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Competitive Advantages: International Approvals/Standards,Experienced R&D Staff,Large Product Line,Contract Manufacturing (CRO,CMO),Quality Service
Other Competitive Advantages: • Specialized in complex biologics including bispecific, trispecific antibodies, and fusion proteins
• Proven track record with over 30 biologics supported through IND or clinical phases globally
• High-expression CHO platforms (>12 g/L) with fast cell line development (as short as 4.5 months)
• Integrated CMC capabilities from DNA to commercial supply
• Expertise in prefilled syringe formulation and aseptic filling – top 3 in China
• Flexible production scale with single-use bioreactors (50–2000 L) and three aseptic fill-finish lines
• Robust QA/QC system aligned with FDA, EMA, and NMPA expectations
• Strong project management and cross-functional communication for global clients
Patents and Copyrights:
Business Type: Service Provider,Manufacturer
R&D capacity: Own Brand
Annual Turnover(USD):
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East,Africa
Other Competitive Advantages: • Specialized in complex biologics including bispecific, trispecific antibodies, and fusion proteins
• Proven track record with over 30 biologics supported through IND or clinical phases globally
• High-expression CHO platforms (>12 g/L) with fast cell line development (as short as 4.5 months)
• Integrated CMC capabilities from DNA to commercial supply
• Expertise in prefilled syringe formulation and aseptic filling – top 3 in China
• Flexible production scale with single-use bioreactors (50–2000 L) and three aseptic fill-finish lines
• Robust QA/QC system aligned with FDA, EMA, and NMPA expectations
• Strong project management and cross-functional communication for global clients
Audited Supplier
Pharma Sources Insight January 2025
